Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CCKAR | P32238 | 2/20 | 0.49 |
| ▸ | CCKBR | P32239 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219003 | 1.00 | CTSS (0.55) | CTSSCTSKCTSLCTSBCCKAR | |
| SCHEMBL4214513 | 1.00 | CTSS (0.55) | CTSSCTSKCTSLCTSBCCKAR | |
| SCHEMBL20630880 | 0.96 | CTSS (0.53) | CTSSCTSKCTSLCTSBCCKAR | |
| SCHEMBL4224327 | 0.91 | KMT2A (0.47) | CTSSCTSKCTSLCTSBKMT2A | |
| SCHEMBL4220175 | 0.91 | KMT2A (0.47) | CTSSCTSKCTSLCTSBKMT2A | |
| SCHEMBL4216654 | 0.91 | KMT2A (0.47) | CTSSCTSKCTSLCTSBKMT2A | |
| SCHEMBL19967948 | 0.91 | CTSS (0.50) | CTSSCTSKCTSLCTSBCCKAR | |
| SCHEMBL13878600 | 0.89 | CTSS (0.59) | CTSSKMT2A | |
| SCHEMBL28778560 | 0.87 | CTSS (0.56) | CTSSCTSKCTSLCTSBCCKAR | |
| SCHEMBL27733231 | 0.87 | CTSS (0.56) | CTSSCTSKCTSLCTSBCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | SLC1A2, NR1H4, OXGR1 | CTSS 4519/4885CTSK 4083/4885CTSL 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.